NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
3.160
0.00 (0.00%)
May 22, 2026, 4:00 PM EDT - Market closed
NewcelX Employees
As of December 31, 2024, NewcelX had 15 total employees, including 11 full-time and 4 part-time employees. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$553,333
Market Cap
17.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 15 | 3 | 25.00% | 11 | 4 |
| Dec 31, 2023 | 12 | -19 | -61.29% | 12 | 0 |
| Dec 31, 2022 | 31 | -1 | -3.13% | 31 | 0 |
| Dec 31, 2020 | 32 | - | - | 28 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Passage Bio | 24 |
| OSR Holdings | 22 |
| IN8bio | 17 |
| Lipocine | 14 |
| Cocrystal Pharma | 10 |
| Exicure | 8 |
| Lexaria Bioscience | 7 |
NCEL News
- 14 days ago - NewcelX files to sell 2.26M common shares for holders - TheFly
- 25 days ago - NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - GlobeNewsWire
- 5 weeks ago - NewcelX announces release of updated presentation on Type 1 Diabetes program - TheFly
- 5 weeks ago - NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - GlobeNewsWire
- 7 weeks ago - NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing - GlobeNewsWire
- 2 months ago - NewcelX announces research agreement with Eledon Pharmaceuticals - TheFly
- 2 months ago - NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PRNewsWire
- 3 months ago - NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy - PRNewsWire